OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic’s Aptima HPV Assay

Key Takeaways

• OM1’s AI platform processed data from 650,000 women for FDA submission
• Automation cut manual abstraction, achieving NPS 87.5 among study sites
• Real‑world evidence enabled Hologic’s Aptima HPV assay FDA approval
• Study leveraged NESTcc framework for device evidence evaluation
• NLP extracted variables from unstructured clinical notes at scale

Pulse Analysis

The FDA’s growing embrace of real‑world evidence (RWE) reflects a broader industry push to validate medical technologies with data that mirrors everyday clinical practice. Historically, device approvals relied on controlled trials that are costly and time‑consuming. By integrating RWE, regulators can assess safety and effectiveness across diverse populations, accelerating access to innovations like Hologic’s Aptima HPV assay, which now benefits millions of women through earlier detection.

OM1’s platform illustrates how artificial intelligence can turn massive, heterogeneous health data into actionable insights. The system ingests electronic health records, laboratory information, and free‑text clinical notes, then applies validated natural language processing models to extract key variables. Automation reduced manual chart abstraction, yielding an impressive Net Promoter Score of 87.5 among participating sites—a proxy for workflow efficiency and user satisfaction. Real‑time dashboards and traceable provenance further ensured data integrity throughout the regulatory review.

For the medical‑device sector, this case study sets a new benchmark. Companies can now contemplate RWE‑centric strategies to lower development costs, shorten time‑to‑market, and demonstrate value in real‑world settings. However, scaling such approaches demands robust data governance, transparent AI validation, and alignment with frameworks like NESTcc. As more firms adopt AI‑driven RWE, the regulatory landscape is poised to evolve, rewarding those that can reliably harness large‑scale patient data while maintaining rigorous scientific standards.